Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Improve Molecular Residual Disease monitoring by combining ctDNA molecular profiling and circulating H3K27Me3-nucleosome levels

Tuesday, March 5, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The poster presented by Grolleau et al. at CNAPS 2024 discusses a novel approach to improve molecular residual disease monitoring in NSCLC. By combining ctDNA molecular profiling with circulating H3K27Me3-nucleosome levels in plasma samples, the study aims to enhance the prognostic capabilities of cancer diagnostics. This innovative method could lead to better patient outcomes.
Price reaction · baseline $19.896 (2024-03-05T16:56:00.000Z) · hit during market hours · 4 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-12.5%
day 1
-0.1%
day 3
+2.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study presents innovative methods for monitoring molecular residual disease.
  • Combining ctDNA profiling with H3K27Me3-nucleosome levels could enhance diagnostic accuracy.
  • The research was presented at a notable conference, CNAPS 2024.

Full Press Release Details

Poster titled: “Improve Molecular Residual Disease monitoring by combining ctDNA molecular profiling and circulating H3K27Me3-nucleosome levels in NSCLC plasma samples.”
Presented at CNAPS 2024
Grolleau et al

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the presented study?

The study focuses on improving molecular residual disease monitoring in NSCLC.

Where was the research presented?

The research was presented at CNAPS 2024.

What methods are being combined in the study?

The study combines ctDNA molecular profiling with H3K27Me3-nucleosome levels.

Who conducted the research?

The research was conducted by Grolleau et al.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare NSCLC ctDNA H3K27Me3 cancer diagnostics
Last updated: Mar 5, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk